# MDT — Medtronic plc

## Company & Research Metadata

- **Company:** Medtronic plc
- **Ticker:** MDT
- **Exchange:** NYSE
- **Sector / Industry:** Health Care / diversified medical devices
- **Template version:** 2.7
- **Research date:** 2026-10-21
- **Valuation / score price snapshot:** $98.88 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Primary operating period reviewed:** Q1 FY2027
- **Historical period reviewed:** TTM, FY 2026, FY 2025; latest balance-sheet date shown below
- **Latest investor presentation reviewed:** Results release and associated financial tables; no separate slide deck materially used
- **Latest earnings call reviewed:** Q1 FY2027, complete material Q&A
- **Latest post-earnings management commentary reviewed:** October 15 separation completion and October 14 exchange results

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 7 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $98.88 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Hold / Watch |
| Bear / Base / Bull Fair Value | $47.53 / $89.50 / $136.73 |
| Scenario Probabilities | 25% / 50% / 25% |
| Probability-Weighted Fair Value | $90.82 |
| Probability-Weighted Expected Return | -8.2% |
| Bear-Case Return | -51.9% |
| Strong Buy Zone | ≤ $52.28 |
| Buy Zone | >$52.28–$72.66 |
| Avoid Chasing Above | > $100.91 |
| Quality Score / Tier | 80.4 / Tier A |
| Opportunity Score / Rank | 44.6 / #52 of 76 |
| Risk Level | Medium-High |
| Tracking / Ownership | Primary Watchlist / Owned |

**Decision rationale:** MDT is **Hold / Watch** at $94.63, with -4.0% probability-weighted upside and -49.8% bear-case return. A durable installed base, cash generation and improving product cycles can support steady per-share returns. Confidence is 58/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

## Investment Thesis

A durable installed base, cash generation and improving product cycles can support steady per-share returns. Q1 FY27 revenue grew 13.7% organically and management raised full-year guidance. The key issue is how much acceleration persists after comparisons normalize and whether innovation translates into better group growth and returns on capital. The stock deserves a durable-device valuation, not a speculative technology multiple.

### What the Market May Be Mispricing

| Debate | Research judgment |
|---|---|
| Durability of organic growth acceleration | A durable installed base, cash generation and improving product cycles can support steady per-share returns. |
| Clinical launches, quality and reimbursement | Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics. |
| FCF, dividend coverage and capital allocation | Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00. |

## Business Overview

Medtronic sells devices across cardiovascular, neuroscience, medical-surgical and diabetes care. Revenue combines implanted devices, procedure-linked products, capital equipment and recurring consumables. Hospitals, physicians and patients adopt products based on clinical outcomes, training, reimbursement and reliability. Diversification reduces dependence on a single product but also makes group growth slower and harder to change through one successful launch. MiniMed became fully independent on October 15, 2026. Diabetes is therefore excluded from the forward Medtronic business perimeter; the historical statements and September earnings guidance still included it. Cardiovascular, Neuroscience and Surgical are the continuing focus.

### Business Takeaway

Medtronic sells devices across cardiovascular, neuroscience, medical-surgical and diabetes care. Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics.

## Industry, TAM & Market Share

Aging populations, chronic disease and minimally invasive procedures support demand. Competition is intense in cardiac, surgical and diabetes technologies. Regulatory approval and reimbursement constrain the pace at which large patient populations become profitable served markets.

### Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| Boston Scientific (BSX) | Direct segments: cardiac rhythm, EP and neuromodulation | Product scope; no matched operating-scale series | Competes for physician adoption | Customer choice in the stated segment only |
| Abbott (ABT) | Direct segments: cardiac rhythm, EP and structural heart | Product scope; no matched operating-scale series | Competition must be evaluated by device | Customer choice in the stated segment only |
| Johnson & Johnson | Direct segments: EP, surgical and selected neuroscience products | Product scope; no matched operating-scale series | Competes in selected procedure categories | Customer choice in the stated segment only |

### Industry Takeaway

Regulatory approval and reimbursement constrain the pace at which large patient populations become profitable served markets. The base case requires evidence of profitable adoption within that market.

## Customer Economics

Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics. Physician training and hospital procurement create switching costs. Pricing pressure and manufacturing quality can offset volume growth, making organic revenue and cash margins more informative than adjusted EPS alone.

### Customer-Economics Takeaway

The economic test is FCF, dividend coverage and capital allocation. Pricing pressure and manufacturing quality can offset volume growth, making organic revenue and cash margins more informative than adjusted EPS alone.

## Competitive Landscape & Moat

### Competitive Landscape

Use the remaining cardiovascular, neuroscience and surgical portfolio. Historical Medtronic diabetes competition must be attributed to independent MiniMed after separation; diversified device exposure alone does not establish full comparability.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Boston Scientific (BSX) | No consistent comparable series | Direct segments: cardiac rhythm, EP and neuromodulation | Focused cardiovascular procedure franchises | Different mix outside overlapping devices | Competes for physician adoption |
| Abbott (ABT) | No consistent comparable series | Direct segments: cardiac rhythm, EP and structural heart | Established cardiovascular products and clinical relationships | Diagnostics/nutrition do not overlap Medtronic devices | Competition must be evaluated by device |
| Johnson & Johnson | No consistent comparable series | Direct segments: EP, surgical and selected neuroscience products | Clinical and hospital distribution | Diversified pharmaceuticals are outside the device comparison | Competes in selected procedure categories |

### Moat Assessment

Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat. Certain franchises face faster innovators, so the portfolio should be evaluated by product rather than assuming uniform leadership.

**Moat direction:** Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

### Competitive Takeaway

Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2027. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2025 | 33,537 | 3.62% | 65.39% | 18.89% | 5,185 | 15.46% | 429 | 1,290 | 8,965 | 29,626 |
| FY2026 | 36,364 | 8.43% | 65.31% | 19.98% | 5,426 | 14.92% | 457 | 1,288 | 9,220 | 29,149 |
| Q1 FY2027 | $9,756 | N/D | N/D | 18.1% | $1,290 (derived: CFO - capex) | 13.2% | $125 | 1,285.1 | $1,691 | N/D |

### Financial Takeaways

Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00. TTM FCF of $6.13 billion supports dividends, debt service and reinvestment. The model uses sustainable EPS after ongoing costs, with a lower multiple than faster-growing medtech peers. The October split exchanged the entire 252.8 million-share MiniMed holding for 55.0 million Medtronic shares. Do not add a retained MiniMed investment or dividend to the model. The 2029 EPS assumptions refer to continuing Medtronic after the smaller share base; previously issued full-company FY27 guidance is not a post-separation forecast.

The historical table predates the October MiniMed split. Forward valuation excludes Diabetes and the former MiniMed stake and incorporates cancellation of 55.0 million Medtronic shares. The earnings release’s $5.94–6.00 FY27 EPS guide is historical full-company guidance, not a verified continuing-company update.

**Financial direction:** Mixed — assess the reported trend alongside dilution and the balance sheet.

## Management & Capital Allocation

Management's improved execution and pipeline progress are encouraging. Portfolio simplification, acquisitions and capital returns should improve per-share economics without starving innovation. Monitor whether faster growth survives the next comparison cycle and whether debt and dividends remain comfortably funded.

### Management Takeaway

Monitor whether faster growth survives the next comparison cycle and whether debt and dividends remain comfortably funded.

## Valuation

### Current Valuation

| Metric | Value |
|---|---|
| Price Snapshot | $98.88 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | $115.84B |
| Enterprise Value | $135.01B |
| Trailing P/E | 23.31 |
| Provider forward P/E | 15.76 |
| EV / Sales | 3.60 |

### Comparable Company Analysis

| Company | Relevance | Public / Private | Forward P/E | EV / Sales | Growth / Margin / Risk Context |
|---|---|---|---|---|---|
| MDT — Medtronic plc | Subject company | Public | 15.76 | 3.60 | diversified medical devices; 3Y revenue-growth estimate 5.20%; operating margin 20.10% |
| BSX — Boston Scientific Corporation | Direct overlapping cardiovascular/neuro segments | Public | 14.14 | 3.72 | medical devices; 3Y revenue-growth estimate 5.49%; operating margin 20.47% |
| ABT — Abbott | Direct cardiovascular segments; broader group multiple | Public | 17.68 | 4.39 | diagnostics, cardiovascular devices and diabetes monitoring; 3Y revenue-growth estimate 9.53%; operating margin 17.68% |
| Johnson & Johnson | Direct segments: EP, surgical and selected neuroscience products | Operating product / listed parent | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Competes in selected procedure categories |

**Comparable takeaway:** Use the remaining cardiovascular, neuroscience and surgical portfolio. Historical Medtronic diabetes competition must be attributed to independent MiniMed after separation; diversified device exposure alone does not establish full comparability. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 18×, versus the provider's current forward P/E of 15.76×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of **$78.36**, versus the central base FV of **$89.50**. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

### Valuation Scenarios

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---|---|---|---|
| Bear | 3Y revenue CAGR 2%; sustainable 2029 EPS $5.00 after compensation; 13× P/E; 11% discount rate; Growth returns to low single digits and 2029 sustainable EPS is $5. | $47.53 | 25% | Execution, financing or competitive setbacks remain credible | -51.9% |
| Base | 3Y revenue CAGR 6%; sustainable 2029 EPS $6.80 after compensation; 18× P/E; 11% discount rate; Steady product execution produces $6.80 of 2029 sustainable EPS. | $89.50 | 50% | Most likely operating trajectory, requiring measurable progress | -9.5% |
| Bull | 3Y revenue CAGR 9%; sustainable 2029 EPS $8.50 after compensation; 22× P/E; 11% discount rate; A stronger portfolio cycle produces $8.50 of 2029 sustainable EPS. | $136.73 | 25% | Successful product conversion and operating leverage; not assured | +38.3% |
| **Probability-Weighted** | Sum of each scenario value × its probability | $90.82 | **100%** | Judgmental scenario probabilities | -8.2% |

### Valuation Takeaway

- **Primary valuation method:** Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
- **Cross-check methods:** Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in [the valuation workpaper](../valuation/watchlist_models_2026-10-21.md).
- **Key valuation dependencies:** Durability of organic growth acceleration; Clinical launches, quality and reimbursement; FCF, dividend coverage and capital allocation. All forward figures are independent research assumptions, not company guidance or consensus.
- **Valuation confidence / Risk Level:** 58/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
- **Margin-of-safety conclusion:** Hold / Watch at $94.63. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

## Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Travis Steed / Bank of America | What supports core growth and margin guidance? | Management said the broad portfolio supports guidance. | Require durable cash conversion after compensation and ongoing investment. |
| Larry Biegelsen / Wells Fargo | What synergies are expected from the Cornerstone acquisition? | Management said distribution synergies should develop over time. | Judge allocation on per-share returns after financing and dilution. |
| Vijay Kumar / Evercore | How does the diabetes separation change the business? | Management said the transaction changes the reporting and operating perimeter. | Confirm that this opportunity converts into profitable recurring demand. |
| Mike Kratky / Leerink | How is Affera adoption supporting the cardiac opportunity? | Management said sequential adoption supports the opportunity. | Confirm that this opportunity converts into profitable recurring demand. |
| Anthony Petrone / Mizuho | How will capital be allocated after the diabetes separation? | Management said the remaining portfolio must replace the separated growth contribution. | Judge allocation on per-share returns after financing and dilution. |
| Matt O'Brien / Piper Sandler | What will drive renal-denervation adoption? | Management said clinical evidence and reimbursement drive adoption. | Confirm that this opportunity converts into profitable recurring demand. |
| Robbie Marcus / JPMorgan | What is the expected margin trajectory for the year? | Management said it is targeting full-year margin improvement. | Require durable cash conversion after compensation and ongoing investment. |

### Analyst-Q&A Takeaway

Cardiac adoption and margin execution support continuing operations. The now-completed Diabetes separation changes comparability and capital allocation; historical full-company guidance is an inadequate standalone forecast.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| Durability of organic growth acceleration | A durable installed base, cash generation and improving product cycles can support steady per-share returns. | Revenue trajectory sustains approximately 6% annual growth on a comparable basis | Growth remains below the 2% bear assumption over a full operating cycle | Revenue outlook and scenario probabilities |
| Clinical launches, quality and reimbursement | Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics. | After-cost earnings progress toward the base implied net margin of 19.0% | Competition, credit losses or service costs make that margin trajectory unattainable | Margins, moat score and valuation multiple |
| FCF, dividend coverage and capital allocation | Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00. | Financing and compensation remain consistent with 1,144.1M economic shares in the 2029 base case | Required capital or cumulative dilution materially exceeds the model without matching earnings | Financial score, confidence and downside value |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---|---|---|---|
| Business durability and economics | 86 | 25% | 21.5 | Procedure volumes, product mix, installed equipment utilization and recurring consumable demand drive customer economics. |
| Moat and competitive position | 85 | 25% | 21.3 | Clinical evidence, regulatory expertise, global distribution and installed systems create a strong diversified moat. |
| Growth runway and durability | 74 | 20% | 14.8 | Aging populations, chronic disease and minimally invasive procedures support demand. |
| Financial quality and balance sheet | 79 | 15% | 11.9 | Q1 FY27 revenue was $9.756 billion and adjusted EPS $1.45; FY27 adjusted EPS guidance was $5.94–6.00. |
| Management, governance and capital allocation | 73 | 15% | 11.0 | Management's improved execution and pipeline progress are encouraging. |
| **Quality Score** | **80.4** | **100%** | **80.4** | Weighted score, independent of ownership and current price |

- **Quality Tier:** A
- **Speculative override:** None

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 80.4 | 80.4 | 30% | 24.1 |
| Probability-weighted upside | -8.2% | 33.7 | 35% | 11.8 |
| Bear-case downside | -51.9% | 0.0 | 20% | 0.0 |
| Risk / valuation confidence | 58 | 58.0 | 15% | 8.7 |
| **Opportunity Score** |  | **44.6** | **100%** | **44.6** |

- **Opportunity Rank:** #52 of 76
- **Zone Status:** Hold / Watch

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Tracking source of truth:** `my_watchlist.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 (America/New_York) | $94.63 | Hold / Watch | Hold / Watch | >$52.28–$72.66 | ≤ $52.28 | > $100.91 | $89.50 | $90.82 | -4.0% | 80.4 | 47.5 / #39 | Initial missing-file analysis; common-universe ranking; independent scenario assumptions |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - Sep 1, 2026](https://news.medtronic.com/2026-09-01-Medtronic-reports-first-quarter-fiscal-2027-results-delivers-broad-based-portfolio-performance-and-raises-fiscal-2027-guidance) | Company IR / earnings filing | Q1 FY2027 | Latest operating results, guidance, products and financial supplement |
| [MDT complete earnings-call transcript](https://stockanalysis.com/stocks/mdt/transcripts/685094-q1-2027/) | Transcript | Q1 FY2027 | Prepared remarks and all material Q&A exchanges |
| [MDT regular-session historical price](https://stockanalysis.com/stocks/mdt/history/) | Market data | 2026-10-20 close | Common price used in returns, scores and zones |
| [MDT valuation statistics](https://stockanalysis.com/stocks/mdt/statistics/) | Market data | 2026-10-20 close; ratios retrieved 2026-10-21 | Market capitalization, shares, quoted multiples and current ratios |
| [MDT historical income statement](https://stockanalysis.com/stocks/mdt/financials/income-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical income statement; source-native currency and definitions |
| [MDT historical balance sheet](https://stockanalysis.com/stocks/mdt/financials/balance-sheet/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical balance sheet; source-native currency and definitions |
| [MDT historical cash flows](https://stockanalysis.com/stocks/mdt/financials/cash-flow-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical cash flows; source-native currency and definitions |
| [Boston Scientific Corporation statistics](https://stockanalysis.com/stocks/bsx/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [Abbott statistics](https://stockanalysis.com/stocks/abt/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [MiniMed separation completion](https://news.medtronic.com/2026-10-15-Medtronic-Completes-Separation-of-MiniMed-Group,-Inc) | Company IR | 2026-10-15 | Continuing business perimeter |
| [Final split-off results](https://news.medtronic.com/2026-10-14-Medtronic-Announces-Final-Results-of-MiniMed-Group,-Inc-Exchange-Offer) | Company IR | 2026-10-14 | 55.0 million Medtronic shares exchanged; no retained MiniMed stake |
| [SEC XBRL company facts — MDT](https://data.sec.gov/api/xbrl/companyfacts/CIK0001613103.json) | Regulatory filing (as tagged) | FY2027, through 2026-07-31 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |